Financial Data and Key Metrics Changes - For Q4 2025, general and administrative expenses were approximately $1.5 million, a slight decrease from $1.6 million in Q4 2024. R&D expenses were approximately $2.7 million, down from $4.3 million in the same period last year. The net loss for Q4 2025 was approximately $4.1 million, or $0.36 per share, compared to a net loss of $5.9 million, or $0.54 per share in Q4 2024 [32][33] - For the full year 2025, R&D expenses totaled approximately $11.5 million, down from $16.1 million in 2024, primarily due to a reduction in research studies and materials. General and administrative expenses increased slightly to approximately $6.5 million from $6.1 million in 2024. The net loss for 2025 was approximately $17.1 million, or $1.57 per share, compared to $20.8 million, or $1.93 per share in 2024 [33][35] Business Line Data and Key Metrics Changes - The company achieved clinical validation across multiple programs, including LP-300 and LP-184, with significant milestones in their clinical trials. The LP-300 program specifically targets lung cancer in never smokers, representing a substantial market opportunity of over $4 billion annually [3][7] - The LP-184 phase I results showed a 48% clinical benefit rate in heavily pretreated advanced cancer patients, validating the synthetic lethality hypothesis and indicating potential for further development in precision oncology trials [10][11] Market Data and Key Metrics Changes - The estimated annual market potential for the company's AI-driven clinical pipeline exceeds $15 billion and approaches $20 billion, with a focus on solid tumors, blood cancers, and pediatric oncology [4] - The company is actively exploring collaboration opportunities globally to maximize the commercial potential of LP-300, with ongoing discussions with regional and global pharma companies [10] Company Strategy and Development Direction - The company is positioning itself to advance clinical programs and expand the RADR platform's commercial reach globally through a new AI Center of Excellence in India, aiming to strengthen its balance sheet and enhance revenue potential [4][24] - The strategic focus includes leveraging AI and machine learning to transform drug development processes, with a vision to create a new paradigm in precision oncology [2][40] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI technologies in drug discovery and the potential for significant returns as the industry matures towards an AI-centric approach. They highlighted the need for rapid advancements in drug development to meet the urgent needs of cancer patients [2][40] - The company plans to pursue additional funding and partnerships to support ongoing clinical trials and operational advancements, indicating a proactive approach to financial sustainability [39][41] Other Important Information - The company cleared an IND for a pediatric CNS cancer trial through Starlight Therapeutics, marking a significant regulatory milestone and positioning the company for further clinical development across various patient demographics [16][22] - The RADR AI platform integrates extensive oncology-focused data and machine learning algorithms, with plans for commercialization and expansion into other therapeutic areas beyond cancer [24][31] Q&A Session Summary Question: What are the upcoming milestones for the LP-300 program? - The company has a Type C meeting scheduled with the FDA to discuss protocol amendments for the LP-300 trial, focusing on specific patient populations and treatment cycles [38] Question: How is the company addressing funding needs? - The company is actively evaluating and pursuing potential funding alternatives to support its anticipated operating expenses and capital requirements [36]

March 30th, 2026 4:30 PM Eastern Time Fourth Quarter & Year-end 2025 Operating & Financial Results Conference Call / Webinar NASDAQ :LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potenti ...

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform Accessibility StatementSkip Navigation About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. ...

Core Viewpoint - Guardant Health, Inc. has contributed real-world evidence through its InfinityAI platform, which played a role in the approval of ENHERTU® for treating HER2-positive advanced or recurrent solid cancers in Japan [1]. Group 1 - Guardant Health is recognized as a leading precision oncology company [1]. - The approval of ENHERTU® (trastuzumab deruxtecan) was developed and commercialized by Daiichi Sankyo [1]. - The treatment is specifically for patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers [1].

Core Insights - Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is recognized as a promising stock under $5 with potential for significant growth [1] - Analysts at Wedbush have raised the price target for BDTX from $13 to $14, maintaining an "Outperform" rating due to optimism regarding the company's clinical pipeline and upcoming catalysts [2] Clinical Progress - The company is focused on precision oncology, with notable advancements in the silevertinib program, which has positively influenced share price performance [3] - Preliminary Phase 2 data for silevertinib in NSCLC patients with uncommon EGFR mutations was reported in December 2025, with further data expected soon, serving as a key catalyst for the stock [3] Financial Performance - For the fourth quarter and full year ending December 31, 2025, BDTX reported a 60% objective response rate, 86% CNS objective response rate, and 91% disease control rate from Phase 2 data [4] - The company has increased cash reserves to $128.7 million and reported a net income of $22.4 million, with a financial runway extending into the second half of 2028 [4] Company Overview - Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target oncogenic mutations, particularly focusing on brain-penetrant EGFR inhibitors for NSCLC and glioblastoma [5]

Clinical-Stage Oncology Company Advancing New Targeted Cancer Therapies A transformative transaction combining proven drug development expertise with a first-in-class therapeutic candidate targeting solid tumours March 2026 Disclaimer NOT FOR RELEASE, PUBLICATIONOR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, OR THE REPUBLIC OF SOUTH AFRICAOR ANY OTHER JURISDICTIONIN WHICH IT WOULD BE UNLAWFUL TO DOSO. For the purposes of this document, t ...

Core Insights - Illumina, Inc. (ILMN) and Labcorp (LH) have expanded their collaboration to enhance precision oncology through next-generation sequencing (NGS) solutions, which is expected to solidify Illumina's position in the oncology market [1][3] Company Developments - Following the collaboration announcement, ILMN's shares increased by 1.8%, closing at $122.95, indicating positive market sentiment [2][10] - Illumina's TruSight Oncology assay, TSO 500, is experiencing increased utilization and broader adoption, contributing to the company's growth in cancer genomics [2] - The collaboration aims to co-commercialize Labcorp's FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumor profiling, expanding access to both tissue and liquid biopsy testing [5] Research and Clinical Utility - The collaboration will focus on developing new tests for advanced oncology research, including comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS) [6] - A study published in Frontiers of Oncology demonstrated that CGP identified variants associated with targeted therapies in over 72% of non-small cell lung cancer (NSCLC) patients, showcasing the clinical utility of CGP [7][8] Market Outlook - The global oncology market is projected to reach $866.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.8% from 2024 to 2034, driven by rising cancer incidence and technological advancements [9] - Illumina currently has a market capitalization of $18.48 billion and an earnings yield of 4.25%, significantly outperforming the industry's -15.13% [4]

Core Insights - Illumina and Labcorp have expanded their collaboration to enhance access to precision oncology testing through next-generation sequencing (NGS) solutions [1][2] Group 1: Collaboration Details - The collaboration aims to promote equitable access to cancer biomarker testing by introducing new distributed test offerings [1] - New test development will focus on advanced oncology research and in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS) [2] - The companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive for solid tumor profiling [3] Group 2: Clinical Utility and Research - A collaborative study evaluated over 7,600 non-small cell lung cancer (NSCLC) tumor samples, demonstrating that CGP detected variants with a current targeted therapy or clinical trial in more than 72% of patient tumors [4] - This collaboration has resulted in eight joint publications in oncology since 2022, along with 18 posters and presentations at industry conferences [5] Group 3: Strategic Goals - The partnership reflects a shared commitment to improving cancer care through innovation and access, aiming to deliver transformative testing solutions for timely and equitable cancer care [4] - The collaboration seeks to generate evidence to facilitate payer coverage and address areas of unmet need in precision oncology [1][2]

Core Insights - Guardant Health will present 28 abstracts at the AACR Annual Meeting 2026, focusing on advancements in tumor typing, therapy selection, and the utility of multiomic tissue and liquid biopsy testing [1][2] Group 1: Presentation Highlights - Key data will showcase the effectiveness of blood- and tissue-based tests in addressing critical gaps in cancer care, including identifying unknown primary cancers and expanding treatment options [2] - Guardant360 Tissue has shown strong performance in determining tissue of origin in challenging diagnostic settings, with a 92% accuracy rate across over 6,000 samples and 24 tumor types [4] - Guardant Reveal demonstrates expanded utility in identifying new primary cancers during minimal residual disease (MRD) monitoring, highlighting its potential for non-invasive detection [4] Group 2: Specific Studies and Findings - Research indicates that a tissue-based genomic instability score can accurately detect DNA repair deficiencies in breast, ovarian, and pancreatic cancers, identifying patients who may benefit from PARP inhibitors [4] - Guardant360 Liquid has actionable findings for 85% of metastatic breast cancer patients and 89% of advanced colorectal cancer patients, showcasing its clinical actionability [4] - The presentations will include a focus on the clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers [5] Group 3: Presentation Schedule - Notable presentations include: - A methylation-based molecular tumor typing classifier for cancers of unknown primary on April 19, 2026 [5] - Tissue-based homologous recombination deficiency status prediction in breast, ovarian, and pancreatic cancers on April 20, 2026 [5] - Exploring clinical actionability of expanded liquid biopsy on April 21, 2026 [5] Group 4: Company Overview - Guardant Health is a leading precision oncology company focused on transforming patient care through advanced blood and tissue tests, real-world data, and AI analytics [10] - The company aims to improve outcomes across all stages of cancer care, from early screening to treatment selection for advanced cancer [10]

Core Insights - Deerfield Management Company disclosed a significant purchase of Celcuity shares, acquiring 980,470 shares valued at approximately $80.60 million in the fourth quarter of 2026 [1][2] - The total value of Deerfield's position in Celcuity reached $170.95 million at the end of the quarter, reflecting an increase of $134.72 million from the previous quarter, driven by both new purchases and share price appreciation [2] Company Overview - Celcuity Inc. is a biotechnology firm focused on precision oncology, utilizing its CELsignia platform and a pipeline of targeted therapeutics to identify specific cellular drivers of cancer for personalized treatment [5] - The company has a market capitalization of $5.3 billion and reported a net income of -$162.72 million over the trailing twelve months [4] Product and Pipeline - Celcuity's lead drug candidate, Gedatolisib, targets the PI3K and mTOR signaling pathways, which are crucial for cancer growth, by blocking multiple components simultaneously [9] - The FDA has accepted Celcuity's new drug application for Gedatolisib in hormone receptor positive, HER2 negative advanced breast cancer, granting it priority review with a decision date set for July 17, 2026 [10] Market Performance - Celcuity's shares have surged over 1,040% in the past year, significantly outperforming the S&P 500's gain of approximately 19% during the same period [7] - The company is expected to release its upcoming quarterly report soon, and as of September 30, it reported having around $455 million in cash and short-term investments, sufficient to fund operations through the next year [11]